Value-Based Care Sales:
How HealthTech Companies Win Payer and Provider Contracts

Why Value-Based Care Is Reshaping HealthTech Buying Decisions

The fee-for-service model created a procurement dynamic where hospitals bought technology to reduce FTE costs, improve throughput, and satisfy regulatory mandates. The ROI calculation was straightforward: labor savings minus software cost equals value. Value-based care breaks that equation entirely.

Under VBC arrangements — capitation, bundled payments, shared savings, pay-for-performance — provider organizations and health plans are financially accountable for the total cost and quality of care for a defined population. That changes what they will pay for. They're not buying efficiency; they're buying outcomes. HealthTech solutions that can't demonstrate impact on total cost of care, readmission rates, quality scores, or attribution accuracy don't get funded from VBC budgets.

The practical implication for HealthTech founders: if your product reduces unnecessary ED visits, improves HEDIS measure performance, supports risk stratification, enables prior authorization efficiency, or helps close care gaps — you have a VBC story. If it doesn't touch any of those levers, you're likely selling into the wrong budget line for this market segment.

The payer market is particularly underserved by HealthTech. Most startups default to the provider sales motion because hospital systems are familiar buyers. But health plans — and increasingly ACOs, IPAs, and clinically integrated networks operating under risk contracts — represent a growing technology budget that is explicitly tied to VBC program performance. Getting your positioning right for this market is covered in our broader compliance-first GTM framework, but the VBC segment has its own distinct requirements.

Understanding the Payer vs. Provider Sales Motion

Selling to health plans and selling to provider organizations under VBC contracts require different champions, different evidence packages, and different contract structures. Most HealthTech founders treat them as the same sale. They're not.

The Claims Data Advantage for Payer Sales

One of the most significant structural advantages of the payer sales motion: health plans have complete claims data that providers often lack. An ACO may only see claims for patients receiving care within its network; a health plan sees 100% of member utilization across every provider. For HealthTech solutions focused on risk stratification, care gap identification, or network optimization, this data access means health plans can often validate your ROI more cleanly than provider organizations — which makes the pilot-to-enterprise conversion faster once you get past procurement.

ACOs as the Bridge Market

Accountable Care Organizations — particularly MSSP participants and Next Gen ACO successors — sit at the intersection of the payer and provider motion. They bear financial risk like payers but operate with provider-side clinical infrastructure. For early-stage HealthTech companies, ACOs can be the ideal beachhead: smaller decision committees than national plans, genuine budget authority tied to shared savings performance, and shorter procurement cycles than hospital systems. The 600+ active MSSP ACOs represent a named, accessible target market with explicit technology budgets linked to outcome performance.

Building a Value-Based Care ROI Narrative

The single most common reason HealthTech companies lose payer and VBC-focused provider deals is a weak or unquantified ROI narrative. Clinical outcomes language — "improves care coordination," "enhances patient engagement," "supports care team workflows" — does not move payer procurement committees. They need numbers that map to their financial accountability.

The Three ROI Levers That Move Payer Committees

• 01
  Medical Cost Reduction (PMPM Impact)

  Quantify the expected reduction in total cost of care. The payer metric is cost per member per month. If your solution reduces avoidable ED visits by 15% in a high-risk diabetic population, and that population has an average PMPM of $800, the math is: number of members × PMPM savings × duration. Lead with this number. Everything else is supporting detail.

• 02
  Quality Score Improvement (Stars / HEDIS)

  For Medicare Advantage plans, each star rating point is worth hundreds of millions in quality bonus payments from CMS. For commercial plans, HEDIS performance affects employer contract renewals. If your solution closes care gaps, improves medication adherence, or supports preventive care completion rates, translate that into star rating points or HEDIS measure percentile shifts. This is a separate budget line from medical cost, and it's often easier to quantify.

• 03
  Administrative Cost Efficiency (Prior Auth, UM)

  Utilization management and prior authorization are massive cost centers for payers. If your solution reduces unnecessary PA requests, automates clinical decision support at the point of ordering, or reduces appeals volume, health plans will calculate the ROI themselves — they know their cost per PA transaction exactly. This lever works for solutions that don't directly touch clinical outcomes but sit in the medical management workflow.

Building the Evidence Package

Payer procurement requires a more rigorous evidence package than most HealthTech companies prepare for hospital sales. At minimum, you need: a retrospective analysis of outcomes from existing customers (even small pilots count), a credible methodology for how you measured impact (randomized comparison group or matched cohort, not pre/post without controls), and a realistic projection model that the payer's actuarial team can stress-test. If you can provide peer-reviewed clinical evidence supporting your clinical model, include it — but internal data from real deployments carries more weight with payers than published research on tangentially related interventions.

Navigating Payer Procurement: RFI → RFP → Pilot → Enterprise Contract

Payer procurement follows a more structured and committee-driven process than most provider sales cycles. Understanding each gate — and what evidence you need at each stage — prevents the most common failure mode: companies that win early interest but stall at Medical Policy Committee review because they didn't build the right assets upstream.

Stage 1: RFI (Request for Information)

Many national and regional health plans issue RFIs when exploring a new clinical program area before committing to a formal procurement. The RFI response is your first filter: plans use it to build a shortlist for the formal RFP. Your RFI response should be tight (under 20 pages), lead with clinical and financial evidence, demonstrate regulatory and security compliance (HIPAA, SOC 2), and include one strong reference customer in a similar population. Do not treat the RFI as a capability showcase — treat it as a targeted argument for why your approach to this specific problem outperforms alternatives.

The pre-RFI relationship matters more than most founders realize. Our guide to winning enterprise RFPs covers the procurement relationship-building required before the RFP drops — the same logic applies in the payer market, with the added requirement that you build a relationship with the VP of Clinical Programs or CMO, not just the procurement team.

Stage 2: RFP Response

Payer RFPs are typically more detailed than provider RFPs, with specific sections on clinical program design, actuarial modeling methodology, implementation timeline, data integration requirements, regulatory compliance, and financial model flexibility. The key differentiation at this stage is the financial model: can you offer outcome-based or shared risk pricing? Payers are increasingly requiring HealthTech vendors to have skin in the game — a fee structure tied to actual PMPM savings or quality score improvement. If you can offer this model (even partially), it moves you up the shortlist.

Stage 3: Pilot Design

Most national health plans require a paid pilot before awarding an enterprise contract. Pilot design is where deals get killed or accelerated. Non-negotiable elements of a good pilot proposal:

• Defined measurement methodology agreed upfront: Both parties sign off on the comparison group methodology before the pilot starts. Post-hoc disputes about whether you caused the savings are the single biggest pilot failure mode.
• Minimum population size for statistical validity: You need enough members to detect a real effect. If the payer wants to start with 500 members and your effect size requires 2,000 to reach significance, push back on the sample size or adjust the timeframe.
• Clear success criteria that trigger enterprise conversion: Define in writing what "success" looks like — not a vague range, but a specific threshold. If you hit X% reduction in avoidable admissions, the enterprise contract triggers automatically.
• Integration requirements scoped before kickoff: Data feeds from claims systems take 3–6 months to set up at most national plans. Scope the IT integration timeline explicitly so it doesn't consume most of the pilot period.

Stage 4: Enterprise Contract

Enterprise payer contracts involve Legal, Compliance, IT Security, and Finance — expect 3–6 months of contract negotiation after the pilot succeeds. The key commercial terms to protect: multi-year commitment with annual escalators, exclusivity window in the plan's geography or population segment (at least 12 months), data rights (you retain the right to use de-identified aggregate data for model improvement), and termination provisions that require documented underperformance, not convenience termination.

Provider Network Partnerships: Bundled Payment and ACO Opportunities

The provider-side VBC market is distinct from the hospital procurement cycle we've covered elsewhere. ACOs, IPAs, and provider organizations operating under bundled payment contracts have technology budget that is explicitly tied to VBC program performance — but the procurement process is less formal and the decision timeline faster than national health plans.

ACO Sales Motion

MSSP ACOs make technology purchasing decisions through a much smaller committee than national health plans: typically the ACO Executive Director, CMO, and sometimes a board vote. The financial case is more direct — ACOs keep a percentage of the shared savings they generate for CMS. If your solution demonstrably contributes to shared savings, the ACO has a clear incentive to pay for it out of the savings pool rather than the operating budget. Structure your pricing proposal to come out of shared savings, not the base operating budget — this changes the conversation entirely.

The ACO sales cycle runs faster than hospital procurement. For independent ACOs and smaller clinically integrated networks, you can move from first meeting to signed pilot in 60–90 days. The hospital-level procurement gates — IT security review, Medical Executive Committee approval, multi-year capex budget cycles — generally don't apply. This makes ACOs the ideal beachhead for building VBC evidence before attacking the national plan market.

Bundled Payment Program Opportunities

CMS BPCI Advanced and commercial bundled payment programs create specific technology needs around episode attribution, post-acute care management, and 90-day readmission prevention. Health systems participating in bundled payment programs have a financial incentive to reduce post-acute spend — skilled nursing facility days, home health utilization, and readmissions are the biggest cost drivers within most bundles. HealthTech solutions that address these levers have a natural budget owner: the VP of Value-Based Care or the episode navigator team that manages bundle performance.

The sales entry point for bundled payment is different from ACO: you're typically selling to a health system rather than an independent organization, which means more hospital-style procurement. Our full breakdown of hospital procurement cycles applies here, with the modification that the budget is coming from a distinct VBC program budget, not the operational capital budget.

Common Deal-Killers in VBC Sales (And How to Avoid Them)

VBC deals fail for different reasons than traditional HealthTech enterprise sales. The failure modes are predictable — and almost all of them are avoidable with the right preparation.

90-Day Action Plan: Launching Your VBC Sales Motion

Most HealthTech companies trying to break into the VBC market spend months in strategic planning and stakeholder mapping without generating a single substantive payer or ACO conversation. The 90-day plan below is built for speed — getting you to a real meeting with a real decision-maker within the first month, and to a signed pilot LOI within 90 days.

Days 1–30: Foundation and Target List

• Translate your three strongest clinical outcomes into payer-facing financial metrics (PMPM impact, MLR effect, Stars uplift) — this is your foundational sales asset
• Build a target list of 15–20 ACOs and regional health plans whose population focus matches your clinical domain — prioritize MSSP ACOs and Blues plans over national commercial carriers for first deals
• Identify the VP of Clinical Programs or CMO at each target organization — LinkedIn, AHIP conferences, AMGA membership directories, and ACO leadership directories on CMS's website are your primary sources
• Prepare a 5-slide executive brief: the problem (in financial terms), your approach, evidence summary (with comparison group methodology), financial model options, and one-page case study from existing deployment
• Confirm HIPAA compliance posture: BAA templates ready, SOC 2 report current, data processing addendum drafted for claims data environments

Days 31–60: Outreach and Discovery

• Launch warm outreach to your top 10 targets — use conference connections, mutual investor intros, or advisor relationships rather than cold LinkedIn outreach; payer executives ignore cold outreach at high rates
• Target AHIP, AMGA Annual Conference, or regional HFMA/ACHE chapter events — one conference with the right attendee list replaces months of cold outreach
• Conduct discovery calls focused exclusively on their current VBC program challenges — not your product demo. Ask: what quality measures are you underperforming on? What are your highest-cost population segments? Where does your current technology stack fall short for risk stratification?
• Map the decision committee at your top 3 prospects — get to CMO and VP of Medical Management within the first two meetings, not just the program director level
• Ask explicitly: "Do interventions like ours require Medical Policy Committee approval at your plan?" — get the answer before you build your timeline

Days 61–90: Pilot Proposal and LOI

• Present a pilot proposal to your top 2 prospects — include defined measurement methodology, population size, success criteria, enterprise conversion trigger, and financial model (base + performance component)
• Offer to co-present the pilot proposal internally to the Medical Policy Committee or CMO review — help your champion sell it upward rather than leaving them alone with the internal politics
• Begin IT and data integration scoping in parallel with commercial negotiation — at a national health plan, the data feed setup will take longer than the contract negotiation
• Target a signed pilot LOI or letter of intent by day 90 — this is a realistic milestone for ACO targets; national health plans may take 30–60 additional days
• Document everything: meeting notes, agreed definitions, verbal commitments from champions — payer procurement committees have high turnover, and the person who approved your approach in month one may not be in the role by month nine when the contract executes

The VBC market rewards preparation and patience — but it punishes founders who conflate activity with progress. An LOI from a regional health plan in 90 days is a real outcome. Twenty "exploratory conversations" with no clear next steps is not. Apply the same rigor to this motion that applies to your product roadmap. For the broader GTM architecture that supports this kind of structured enterprise pipeline, see our playbooks on enterprise RFP strategy and hospital procurement cycles — the payer motion is distinct, but the underlying discipline is identical.